A Non-randomized Two Part Multi-Center, Open-label, Single Dose Trial With an Escalation Part in Untreated Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients (Part A), Followed by a Parallel Group Part in Untreated and Pre-treated Patients With PAH and CTEPH (Part B) to Investigate the Safety, Tolerability and Pharmacodynamics of Inhaled BAY1237592
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs BAY 1237592 (Primary) ; Nitric oxide
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms ATMOS
- Sponsors Bayer
- 05 Nov 2019 Planned End Date changed from 6 Aug 2020 to 8 Feb 2021.
- 05 Nov 2019 Planned primary completion date changed from 22 Jun 2020 to 22 Dec 2020.
- 31 Jul 2019 Planned End Date changed from 6 Mar 2020 to 6 Aug 2020.